Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Karyopharm Therapeutics (KPTI) over the last 13 years, with Q4 2025 value amounting to $5.0 million.

  • Karyopharm Therapeutics' Cash from Investing Activities fell 6620.94% to $5.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $43.4 million, marking a year-over-year decrease of 5456.52%. This contributed to the annual value of $43.4 million for FY2025, which is 5456.52% down from last year.
  • Latest data reveals that Karyopharm Therapeutics reported Cash from Investing Activities of $5.0 million as of Q4 2025, which was down 6620.94% from $4.8 million recorded in Q3 2025.
  • In the past 5 years, Karyopharm Therapeutics' Cash from Investing Activities registered a high of $51.3 million during Q2 2024, and its lowest value of -$65.3 million during Q4 2022.
  • In the last 5 years, Karyopharm Therapeutics' Cash from Investing Activities had a median value of $15.0 million in 2024 and averaged $9.2 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 31221.32% in 2022, then surged by 19725.44% in 2024.
  • Karyopharm Therapeutics' Cash from Investing Activities (Quarter) stood at $30.8 million in 2021, then tumbled by 312.21% to -$65.3 million in 2022, then soared by 141.11% to $26.8 million in 2023, then plummeted by 44.88% to $14.8 million in 2024, then plummeted by 66.21% to $5.0 million in 2025.
  • Its last three reported values are $5.0 million in Q4 2025, $4.8 million for Q3 2025, and $18.3 million during Q2 2025.